Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial

What happened

Eli Lilly reported 52-week results from the Phase 3b TOGETHER-PsA trial, which compared Taltz plus Zepbound with Taltz alone in people with active psoriatic arthritis. At Week 52, 39.2% of combination patients met the disease-activity and weight-loss outcome, versus 1.7% on Taltz alone.

Confirmed

Global impact / market context

The results suggest a potential clinical and commercial role for combining Lilly’s two therapies in patients with psoriatic arthritis and weight concerns. If further evidence supports the approach and it becomes available for use, broader treatment could add demand for both medicines, while requiring evidence on safety and practical use.

Analyst inference

The reported trial compared the combination with Taltz alone, and Lilly said disease-activity responses began to separate by Week 4, before clinically meaningful weight loss. That timing may be relevant to understanding the treatment’s effects, but these results alone do not establish broader effectiveness or commercial uptake.

Analyst inference

What to watch

1. Watch for fuller trial reporting on safety, patient numbers, and the Week 52 results; these details would help assess how robust and useful the findings are. Analyst inference
2. Watch for any regulatory or clinical guidance on using the medicines together; the article reports trial results but does not say the combination is approved for this use. Analyst inference
3. Track whether Lilly reports further evidence or commercial plans for this combination, since adoption could affect demand for Taltz and Zepbound if use expands. Analyst inference

Evidence

• Original source link unavailable